Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 6Other hematologic neoplasm 3Classical hematology 2

Conditions

Myeloproliferative Disorders 2Anemia 2Primary Myelofibrosis 1Myelodysplastic Syndromes 1

Interventions

Cyclophosphamide 24fludarabine phosphate 18Whole-Body Irradiation 17fludarabine 16Mycophenolic Acid 16Tacrolimus 12Peripheral Blood Stem Cell Transplantation 12Busulfan 12Melphalan 11apixaban 10Biopsy 7Rivaroxaban 6Granulocyte Colony-Stimulating Factor 6Specimen Handling 5Filgrastim 5Cyclosporine 5Azacitidine 5thymoglobulin 4X-Rays 4Sirolimus 4Rituximab 4Injections 4Enoxaparin 4Decitabine 4Bone Marrow Transplantation 4Aspirin 4Antilymphocyte Serum 4venetoclax 3pegylated granulocyte colony-stimulating factor 3hetrombopag 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
luspatercept × Classical hematology × 1 year × Clear all
NCT05732961 2026-05-05

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
6 enrolled
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT04717414 2025-07-10

INDEPENDENCE

Celgene

Phase 3 Active not recruiting
313 enrolled
Classical hematologyMyeloid

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡